Statins and Selective Cyclooxygenase-2 Receptor Inhibitors in Blunt Chest Trauma

Study Overview
=================
Brief Summary
-----------------
Background: Lung contusion affects 17%-25% of adult blunt trauma patients, and is the leading cause of death from blunt thoracic injury. Statins are lipid-lowering drugs with recently suggested anti-inflammatory and antioxidant properties. Cyclo-oxygenase-2 (COX-2) is a key enzyme in the production of prostaglandins (PG), and evidence suggests that COX-2 plays an important role in the pathogenesis of acute lung injury (ALI). Aims: The current study aims at evaluating the beneficial effects of statins and COX-2 receptor inhibitors on ALI elicited by blunt trauma to the chest. Methods: After approval by the institutional ethics and a scientific committee, and obtaining informed consent , patients admitted to the emergency department (ED) due to blunt trauma with a diagnosis of lung contusion will be enrolled in the study.The effects of statins and COX 2 inhibitors on ALI will be assessed by recording clinical parameters and measuring inflammatory mediators levels in the serum and in the bronchoalveolar space. Expected results: The investigators expect to find that the proposed treatment will be effective in reducing ALI burden. The investigators also suppose that using a combination of those drugs will synergistically potentiate their effect on ALI.

Conditions
-----------------
Blunt Chest Trauma, Acute Respiratory Distress Syndrome

Intervention / Treatment
-----------------
* Drug: standard care treatment
* Drug: Celecoxib
* Drug: Rosuvastatin
* Drug: Combined therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients older than 18 years of age Diagnosis of lung contusion by physical examination, chest xrays, history by the patient, accompanying persons or police. Ability to understand and accept the trial procedures and to sign an informed consent form in accordance with national legislation. Admission to ward Exclusion Criteria: Penetrating trauma Current use of lipid-lowering therapy, use of non steroidal anti-inflammatory drugs. Current use of postmenopausal hormone-replacement therapy Evidence of hepatic dysfunction (an alanine aminotransferase level more than twice the upper limit of the normal range), a creatine kinase level more than three times the upper limit of the normal range. Creatinine level higher than 2.0 mg/dl Known uncontrolled hypertension (systolic blood pressure >190 mm Hg or diastolic blood pressure >100 mm Hg History of uncontrolled hypothyroidism (thyroid-stimulating hormone level> 1.5 times the upper limit of the normal range) Psychiatric disorders Pregnancy Known allergy or intolerance to one of the protocol drug

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: control<br>Group 1: control :(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal) | Drug: standard care treatment<br>* Group 1: control :(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)<br>|
| Active Comparator: Celecoxib<br>Group 2: Celecoxib 200 mg × 2/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal) | Drug: Celecoxib<br>* Celecoxib 200 mg × 2/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)<br>|
| Active Comparator: rosuvastatin<br>Group 3: Rosuvastatin 40mg × 1/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal) | Drug: Rosuvastatin<br>* Rosuvastatin 40mg × 1/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)<br>|
| Active Comparator: Combined therapy<br>Group 4: Combined therapy with Celecoxib 200 mg× 2/d + Rosuvastatin 40× 1/d +:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal) | Drug: Combined therapy<br>* Combined therapy with Celecoxib 200 mg× 2/d + Rosuvastatin 40× 1/d +:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 1. Signs of ALI, i.e., pneumonia, adult respiratory distress syndrome [ARDS] | 1. Signs of ALI, i.e., pneumonia, adult respiratory distress syndrome [ARDS] according to following criteria: Suspected or proven infection Hypoxemia: PaO2/FiO2is ≤300 mm HgBilateral infiltrates consistent with pulmonary edema Positive-pressure mechanical ventilation through an endotracheal tube No clinical evidence of left atrial hypertension to explain bilateral infiltrates Presence of at least three of the four SIRS criteria. If only two criteria are evidenced, one must be temperature or WBC | 3 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Lung, Contusion, Injury, Cyclooxygenase, Statin